



JANE-2: JOINT ACTION ON EU NETWORKS OF EXPERTISE ON CANCER (2024-2028)



Kouli E.¹, Outsika, C.², Pletsa V.¹, Rigatou E.², Panourgias E.⁴, Georgiadis P.¹, Memos N.⁴, Sarigiannis D.¹, Stratigos, A.⁵, Souliotis VL. ¹, Papadodima O.¹, Psyrri, A.³, Katsila T.¹, Saloustros, E., Voutsina A.¹, Mitsiou D.¹, Lontos M.⁶, Kosmidou V.¹, Voutetakis K.¹, Konstadoulakis M.⁴, Papanikolaou I.³, Bamias A.³, Kattamis, A.², Pintzas A.¹

¹ Institute of Chemical Biology, National Hellenic Research Foundation, Athens, ² 'Aghia Sophia' Children's Hospital, National and Kapodistrian University of Athens, School of Medicine, ³ Attikon University Hospital, NKUA, School of Medicine, ⁴ Aretaieion University Hospital, Medical School, NKUA, ⁵ “Andreas Sygros” Hospital for Skin Diseases, Medical School, NKUA

ABSTRACT

Introduction: JANE-2 (2024-2028) is a follow-up Joint Action of JA JANE (2022-2024), coordinated by the Fondazione IRCCS Istituto Nazionale Tumori in Milan, involving 121 partners, 29 European countries, including NHRF (PI A. Pintzas) and NKUA (PI A. Kattamis) from Greece, EU co-financed with 40.5 M Euros within Europe’s Beating Cancer Plan (EBCP).

Aim: Building on JANE outcomes and achievements , JANE-2 aims to build seven new Networks of Expertise (NoEs) on: 1) complex and poor prognosis cancers; 2) palliative care; 3) survivorship; 4) personalised primary and secondary cancer prevention; 5) omics technologies; 6) hi-tech medical resources; 7) adolescents and young adults (AYA) with cancer.

Scope: The new NoEs will provide services to the European oncology community, putting patients at the centre: clinical practice guidelines and recommendations, quality of care criteria, educational support, research promotion and support to patient advocates.

Main Challenge: By the end of JANE-2, NoEs will have to be largely independent and able to collaborate with each other, EU networks like EUNetCCC and ERNs and the European oncology community.

Acknowledgements: The project is funded by HaDEA, EU4Health Programme (Grant Agreement: 101183265).

ABOUT THE PROJECT

JANE-2 (2024-2028) (<http://jane-2.eu/>), the follow-up Joint Action of JANE (2022-2024), EU co-financed with 40.5 M Euros within Europe’s Beating Cancer Plan (EBCP), is coordinated by the Fondazione IRCCS Istituto Nazionale Tumori in Milan involving 121 partners from 29 European countries. NHRF (PI A. Pintzas) and NKUA (PI A. Kattamis) are the partners from Greece.

AIM

Building on JANE outcomes and achievements , JANE-2 aims to build seven new Networks of Expertise (NoEs) on:

- 1) complex and poor prognosis cancers
- 2) palliative care
- 3) survivorship
- 4) personalised primary and secondary cancer prevention
- 5) omics technologies
- 6) hi-tech medical resources
- 7) adolescents and young adults (AYA) with cancer.

SCOPE

The new NoEs will provide services to the European oncology community, putting patients at the centre: clinical practice guidelines and recommendations, quality of care criteria, health care and economic models, educational support, research promotion, support to patient advocates, support to political advocacy, and most importantly – everything with patients at the centre.

CONTACT


Evgenia Kouli
Institute of Chemical Biology
National Hellenic Research Foundation
Email: ekouli@eie.gr
Phone: 30-210-7273745
Website: <http://www.eie.gr/>

PROJECT FRAMEWORK

29 European countries
21 beneficiaries and 100 affiliated partners



JANE-2 consists of 4 cross cutting WPs (WP1 project management and coordination, WP2 Dissemination and Communication, WP3 Evaluation, WP4 Sustainability) and 7 WPs each of which corresponds to a NoE.



WP1
Project
Management
& Coordination

WP2
Dissemination &
Communication

WP3
Evaluation

WP4
Sustainability

WP5
NoE on Complex & Poor-
Prognosis Cancers

WP6
NoE on Palliative Care

WP7
NoE on Survivorship

WP8
NoE on Personalised
Primary and Secondary
prevention

WP9
NoE on Omics
Technologies

WP10
NoE on Hi- Tech Medical
Resources

WP11
NoE on Adolescents &
Young adults with cancer

JANE-2 was launched in Milan, Italy, on January 28-29, 2025.

- ❖ NHRF is the leader of WP2-Dissemination &Communication and participates in WP1, WP3, WP4, WP5, WP8 (task leader of T8.3 Lifestyle aspects), WP9, WP10 (co leader of the domain of ex-vivo testing of agents) and WP11.
- ❖ NKUA participates in WP5, WP6, WP7 (task leader of T7.4 Capacity-building programme on integrative cancer survivorship care), WP8, WP10 (co leader of the domain of radiomics) and WP11 (task leader of T11.4 Development of training on cancer in AYA)

MAIN CHALLENGE

By the end of JANE-2, NoEs will have to be sustainable, largely independent and able to develop synergies with EU networks (EUNetCCC, ERNs) and the European oncology community.

ACKNOWLEDGEMENTS

The project is funded by HaDEA, EU4Health Programme (Grant Agreement: 101183265)



Co-funded by
the European Union

